biotech · ALK-positive Non-small Cell Lung Cancer · Biliary Tract Carcinoma
Zelgen Biopharmaceuticals
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Suzhou Zelgen Biopharmaceuticals is a biotech organization headquartered in CN. Primary therapeutic focus areas include ALK-positive Non-small Cell Lung Cancer, Biliary Tract Carcinoma, Advanced Solid Tumor. NovaPharmaNe
Kunshan, CN HQ
8 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Kunshan, CN
- Employees
- 8
- Programs
- 3
- Drugs
- 7
- Patents
- 0
ZG0895 Hydrochloride for Injection
Phase 1 · small molecule · Advanced Solid Tumor
ZG0895 Hydrochloride for Injection for Advanced Solid Tumor is a Phase 1 program (small_molecule) at Suzhou Zelgen Biopharmaceuticals Co.,Ltd with 1 ClinicalTrials.gov record(s).
Internal code ZG0895-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Advanced Solid Tumor
- Status
- active
- Trials
- 1